Free same-day US shipping on orders over $150.00 · bulk pricing on 2+ vials
Kairo Labs
Shop
For research use only. Not for human or animal consumption.
Compound explainer

BPC-157: Mechanism & Research Overview

BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid chain — derived from a partial sequence of a protein known as body protection compound, originally identified in gastric juice. In the research literature it is studied in cellular and animal models for its effects on angiogenesis and tissue-repair signaling pathways, and it is notable for unusual stability relative to many peptides. This overview summarizes its structure, the mechanisms investigated in models, and its molecular data as a reference-material explainer for research use only.

Structure and origin

BPC-157 is a synthetic peptide of 15 amino acids (sequence GEPPPGKPADDAGLV) corresponding to a partial fragment of body protection compound, a protein originally described in gastric juice. It is fully synthetic as supplied — it is not extracted from tissue — and the sequence is the defining identity confirmed on a Certificate of Analysis.

Because it is a partial sequence rather than a native full-length protein, it is sometimes described in the literature as a stable gastric pentadecapeptide.

  • 15-amino-acid pentadecapeptide.
  • Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV).
  • Partial sequence of body protection compound, first identified in gastric juice.
  • Supplied as a fully synthetic peptide.

Mechanisms studied in models

The research literature examines BPC-157 primarily in the context of angiogenesis — the formation of new blood vessels — and tissue-repair signaling. In cellular and animal models, studied mechanisms include modulation of angiogenic signaling associated with the vascular endothelial growth factor (VEGF) pathway and nitric oxide (NO) system, and interactions with growth-factor and cytoprotective signaling.

These are mechanistic findings reported in preclinical and in-vitro systems. They describe what the literature investigates about the molecule's biology in models and are not claims about any effect in humans.

  • Angiogenesis / new blood-vessel formation signaling in models.
  • Associations with the VEGF pathway in preclinical systems.
  • Interactions with the nitric oxide (NO) system.
  • Cytoprotective and growth-factor signaling studied in vitro and in animals.

Notable stability

A frequently noted property of BPC-157 is its relative stability. In the literature it is described as stable in aqueous solution and in gastric-juice conditions where many peptides would degrade rapidly, a feature attributed to its sequence and the absence of especially labile motifs.

This relative robustness makes it a comparatively forgiving research peptide to handle, though standard practice — gentle reconstitution, cold storage, minimal freeze-thaw, and protection from light — still applies to preserve the purity and identity established on its COA.

  • Described as stable in aqueous and gastric-juice conditions in the literature.
  • Relatively robust compared with many peptides.
  • Standard gentle handling and cold storage still recommended.

BPC-157 vs TB-500

BPC-157 is often studied and discussed alongside TB-500, a synthetic thymosin β4 fragment, because both are examined in tissue-repair research contexts. They are, however, structurally and mechanistically distinct: BPC-157 is a 15-residue partial sequence of body protection compound associated with angiogenic and cytoprotective signaling, whereas TB-500 relates to the actin-binding thymosin β4 system.

The two are sometimes co-studied and are also offered as a blend for research. The dedicated comparison page develops the mechanistic differences in detail.

  • BPC-157: pentadecapeptide, angiogenic/cytoprotective signaling in models.
  • TB-500: thymosin β4 fragment, actin-binding system.
  • Structurally and mechanistically distinct; sometimes co-studied as a blend.

What the literature investigates

Peer-reviewed and preclinical work on BPC-157 characterizes its effects on angiogenesis, tissue-repair markers, and cytoprotective signaling in a range of cellular and animal models, along with its stability and physicochemical behavior. As a reference material it is used to probe these pathways and as a comparator in tissue-repair research.

All such work is laboratory and preclinical. Kairo Labs supplies BPC-157 as a research reference compound for research use only; it is not for human or animal consumption, and nothing here constitutes a health or therapeutic claim or any dosing guidance.

Verification and quality

Identity and purity should be confirmed per lot: a Certificate of Analysis reporting HPLC purity with its chromatogram, mass-spectrometric identity comparing observed against theoretical mass (~1419.5 g/mol), and net peptide content establishes that the material is the correct pentadecapeptide at the stated purity. Kairo Labs verifies to the lot, so every batch is tested and its data retrievable.

See the COA guide for how to read those measurements and the handling guides for reconstitution, storage, and stability.

Frequently asked
What is BPC-157?

BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid chain (sequence GEPPPGKPADDAGLV) — corresponding to a partial fragment of body protection compound, a protein originally identified in gastric juice. It is supplied as a fully synthetic research reference peptide.

What mechanisms does the literature study for BPC-157?

Research in cellular and animal models focuses on angiogenesis and tissue-repair signaling, including associations with the VEGF pathway and the nitric oxide system, and cytoprotective and growth-factor signaling. These are mechanistic findings in preclinical models, not claims about effects in humans.

Why is BPC-157 considered notably stable?

The literature describes it as stable in aqueous solution and in gastric-juice conditions where many peptides degrade rapidly, attributed to its sequence. It is comparatively robust to handle, though standard gentle reconstitution, cold storage, and light protection still apply.

How does BPC-157 differ from TB-500?

BPC-157 is a 15-residue partial sequence of body protection compound associated with angiogenic and cytoprotective signaling, while TB-500 is a synthetic thymosin β4 fragment related to the actin-binding thymosin β4 system. They are structurally and mechanistically distinct though sometimes co-studied.

Is BPC-157 available for any human or animal use?

No. BPC-157 is supplied strictly as a research reference material for research use only. It is not for human or animal consumption, and this page describes only structure, mechanism studied in models, and molecular data — no therapeutic claims or dosing.

Research Use Only. All products and information referenced by Kairo Labs are intended strictly for laboratory research and educational purposes. They are not for human or animal consumption, and not for diagnostic, therapeutic, or clinical use. This content describes mechanisms, molecular properties, and handling as studied in the scientific literature; it is educational, not medical advice, and not a recommendation to use any compound in humans or animals. Researchers are responsible for handling all materials in accordance with applicable laws, regulations, and institutional safety protocols.